ABSTRACT
Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. OBJECTIVES: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. METHODS: We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. RESULTS: In total, 205 patients were included of whom 39 (19%) were treatment-naïve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. CONCLUSIONS: In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.
Subject(s)
Adenine/analogs & derivatives , Antineoplastic Agents/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology , Piperidines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Adenine/administration & dosage , Adenine/adverse effects , Adenine/therapeutic use , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Molecular Targeted Therapy , Piperidines/administration & dosage , Piperidines/adverse effects , Prognosis , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/adverse effects , Public Health Surveillance , Retrospective Studies , Treatment OutcomeABSTRACT
In this case report, a 26-year-old pregnant woman presented with headache, visual disturbances, mega-loblastic anaemia, thrombocytopenia and proteinuria in her third trimester. These symptoms were initially misinterpreted as HELLP-syndrome, but due to normal blood pressure and liver function the patient was diagnosed with severe folate deficiency despite her daily supplements of folate to avoid neural tube defects and deficiency. The reason was onset of coeliac disease during pregnancy. Careful examination may help discriminate HELLP-syndrome from folate deficiency and thus avoid preterm delivery.
Subject(s)
Folic Acid Deficiency , HELLP Syndrome , Pre-Eclampsia , Adult , Diagnosis, Differential , Female , Folic Acid , Folic Acid Deficiency/diagnosis , Humans , Pre-Eclampsia/diagnosis , Pregnancy , Pregnancy Trimester, ThirdABSTRACT
In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox's proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6%. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.
Subject(s)
Drug Resistance, Neoplasm , Hematopoietic Stem Cell Transplantation/mortality , Hospitalization/statistics & numerical data , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Non-Hodgkin/mortality , Severity of Illness Index , Aged , Cohort Studies , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Large B-Cell, Diffuse/therapy , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Prognosis , Survival Rate , Transplantation, AutologousABSTRACT
Webcasting is an educational activity where the teacher and the participants are separated in space and time when using modern information technology. It is widely used for all learning levels and in all educational forms of haematology training in Europe. A working group in the Education Council of internal medicine, haematology in the eastern part of Denmark initiated a project with webcasting from local haematological departments. The aim of the education project was to contribute to spreading knowledge and support the training of specialist in haematology. Our experience is hereby reported.
Subject(s)
Hematology/education , Webcasts as Topic , Denmark , Humans , Medical Staff, Hospital , Physicians , Pilot ProjectsABSTRACT
We present a 56-year-old woman who received chemotherapy for relapsed diffuse large B-cell lymphoma and developed posterior reversible encephalopathy syndrome (PRES) with generalized seizures 27 days after treatment with rituximab, ifosfamide, carboplatin and etoposide (R-ICE). The patient had moderate renal impairment (eGFR > 30 ml/min.) and a normal blood pressure. PRES was confirmed by MRI, which showed oedema of the occipital, parietal and frontal lobes. A control MRI after four weeks showed full remission. To our knowledge this is the first published case of R-ICE causing PRES.
